Related Experiment Video
Updated: Jun 12, 2026
08:49
Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
Published on: September 23, 2015
Brain serotonin receptors in Huntington's disease
A J Cross1, G P Reynolds, L M Hewitt
1Department of Physiology, University of Manchester, Manchester M13 9PT England.
Neurochemistry International
|May 25, 2010
Summary
Huntington's disease patients show reduced serotonin S1 receptors in the putamen and hippocampus. Serotonin S2 receptors remained unchanged, suggesting S1 receptors are on susceptible cells in these brain regions.
Area of Science:
- Neuroscience
- Neuropharmacology
- Neuropathology
Background:
- Huntington's disease is a neurodegenerative disorder affecting specific brain regions.
- Serotonin receptors play crucial roles in brain function and are implicated in various neurological conditions.
Purpose of the Study:
- To investigate the levels of serotonin S1 and S2 receptors in post-mortem brain samples from Huntington's disease patients and controls.
- To determine if changes in these receptors correlate with the pathology of Huntington's disease.
Main Methods:
- Post-mortem brain tissue analysis from Huntington's disease patients and healthy controls.
- Quantitative assessment of serotonin S1 and S2 receptor densities in specific brain regions (putamen, hippocampus, frontal cortex, temporal cortex).
Main Results:
- A significant reduction in serotonin S1 receptors was found in the putamen and hippocampus of Huntington's disease patients compared to controls.
- No significant changes in serotonin S1 receptors were observed in the frontal and temporal cortices.
- Serotonin S2 receptor levels were unchanged across all studied brain regions in Huntington's disease patients.
Conclusions:
- The findings suggest that serotonin S1 receptors are downregulated in brain regions critically affected by Huntington's disease, such as the putamen and hippocampus.
- These results indicate that serotonin S1 receptors may be located on neuronal populations susceptible to the neurodegenerative processes in Huntington's disease.
Related Concept Videos
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...